Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Stefan Balabanov, MD, PhD, Artur Gontarewicz, MD, Patrick Ziegler, PhD, Ulrike Hartmann, PhD, Mhairi Copland, MD, Ute Brassat, Ilona Hauber, PhD, Lothar Kanz, MD, Carsten Bokemeyer, MD, Alfred Nordheim, PhD, Joachim Hauber, PhD, Tessa L. Holyoake, MD, Tim H. Brummendorf, MD

Blood (2006) 108 (11): 1379.

https://doi.org/10.1182/blood.V108.11.1379.1379

Published: 2006

Journal Articles

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Stefan Balabanov, Artur Gontarewicz, Patrick Ziegler, Ulrike Hartmann, Winfried Kammer, Mhairi Copland, Ute Brassat, Martin Priemer, Ilona Hauber, Thomas Wilhelm, Gerold Schwarz, Lothar Kanz, Carsten Bokemeyer, Joachim Hauber, Tessa L. Holyoake, Alfred Nordheim, Tim H. Brümmendorf

Blood (2006) 109 (4): 1701–1711.

https://doi.org/10.1182/blood-2005-03-037648

Published: 2006

Journal Articles

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Stefan Balabanov, MD, PhD, Patrick Ziegler, PhD, Ulricke Hartmann, Winfried Kammer, PhD, Mhairi Copland, MD, Martin Priemer, Thomas Wilhelm, Carsten Bokemeyer, MD, Lothar Kanz, MD, Tessa Holyoake, MD, Alfred Nordheim, PhD, Tim Bruemmendorf, MD

Blood (2005) 106 (11): 1997.

https://doi.org/10.1182/blood.V106.11.1997.1997

Published: 2005

Journal Articles

Identification of BCR-ABL Dependent Gene Regulation by Using a Phosphoproteomics Approach.

Patrick Ziegler, PhD, Stefan Balabanov, MD PhD, Ulrike Hartmann, Winfried Kammer Kammer, PhD, Alfred Nordheim, PhD, Tim H. Brummendorf, MD

Blood (2004) 104 (11): 2944.

https://doi.org/10.1182/blood.V104.11.2944.2944

Published: 2004

Journal Articles

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

Stefan Balabanov, MD PhD, Ulrike Hartmann, Winfried Kammer, PhD, Patrick Ziegler, PhD, Martin Priemer, Gerold Schwarz, Lothar Kanz, MD, Alfred Nordheim, PhD, Tim H. Brummendorf, MD

Blood (2004) 104 (11): 2957.

https://doi.org/10.1182/blood.V104.11.2957.2957

Published: 2004

Journal Articles

AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells

Olaf Heidenreich, Jürgen Krauter, Heidemarie Riehle, Philipp Hadwiger, Matthias John, Gerhard Heil, Hans-Peter Vornlocher, Alfred Nordheim

Blood (2003) 101 (8): 3157–3163.

https://doi.org/10.1182/blood-2002-05-1589

Published: 2003

Journal Articles

Cyclosporin A blocks the expression of lymphotoxin α, but not lymphotoxin β, in human peripheral blood mononuclear cells

Dmitry V. Kuprash, Veronica E. Boitchenko, Felix O. Yarovinsky, Nancy R. Rice, Alfred Nordheim, Andreas Rühlmann, Sergei A. Nedospasov

Blood (2002) 100 (5): 1721–1727.

https://doi.org/10.1182/blood.V100.5.1721.h81702001721_1721_1727

Published: 2002

NARROW

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Identification of BCR-ABL Dependent Gene Regulation by Using a Phosphoproteomics Approach.

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells

Cyclosporin A blocks the expression of lymphotoxin α, but not lymphotoxin β, in human peripheral blood mononuclear cells

Email alerts

ASH Publications

American Society of Hematology

Combination of Imatinib and Hypusination Inhibitors Represents a Novel Therapeutic Strategy in Bcr-Abl Positive Leukemias.

Hypusination of eukaryotic initiation factor 5A (eIF5A): a novel therapeutic target in BCR-ABL –positive leukemias identified by a proteomics approach

Inhibition of Hypusination of Eukaryotic Initiation Factor 5a (eIF-5A) as a Novel a Synergistic Treatment Strategy in Imatinib-Treated BCR-ABL Positive Leukemias Identified by a Global Proteomics Approach.

Identification of BCR-ABL Dependent Gene Regulation by Using a Phosphoproteomics Approach.

Identification of Hypusination Inhibitors as a Novel Therapuetical Option in BCR-ABL Positive Leukemias Using a Proteomics Approach.

AML1/MTG8 oncogene suppression by small interfering RNAs supports myeloid differentiation of t(8;21)-positive leukemic cells

Cyclosporin A blocks the expression of lymphotoxin α, but not lymphotoxin β, in human peripheral blood mononuclear cells

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only